The predictive value of serum inflammatory markers for the severity of cervical lesions.
Humans
Female
Uterine Cervical Neoplasms
/ blood
Retrospective Studies
Adult
Middle Aged
ROC Curve
Predictive Value of Tests
Uterine Cervical Dysplasia
/ blood
Early Detection of Cancer
/ methods
Colposcopy
Severity of Illness Index
Biomarkers, Tumor
/ blood
Neutrophils
/ pathology
Inflammation
/ blood
Cervical lesions
Colposcopy
MLR
NLR
PLR
SII
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
28 Jun 2024
28 Jun 2024
Historique:
received:
16
04
2024
accepted:
25
06
2024
medline:
29
6
2024
pubmed:
29
6
2024
entrez:
29
6
2024
Statut:
epublish
Résumé
Exploring the predictive value of NLR, PLR, MLR, and SII for the severity of cervical cancer screening abnormalities in patients. A retrospective analysis was conducted on the data of 324 patients suspected of cervical lesions due to abnormal TCT and/or HPV in our hospital from January 2023 to December 2023, who underwent colposcopy. The pathological results of colposcopic biopsy confirmed that there were 140 cases of chronic cervicitis, which classified as the group without cervical lesions. The cervical lesion group included 184 cases, including 91 cases of LSIL, 71 cases of HSIL, and 22 cases of cervical cancer. Compared the differences in preoperative peripheral blood NLR, PLR, MLR, and SII among different groups of patients, and evaluated their predictive value for the severity of cervical lesions using Receiver Operating Characteristic (ROC) curves. The levels of NLR, PLR, and SII in the group without cervical lesions were lower than those in the group with cervical lesions (p < 0.05), and there was no statistically significant difference in MLR (p > 0.05). The comparison of NLR among LSIL, HSIL, and cervical cancer groups showed statistically significant differences (p < 0.05), while PLR, MLR, and SII showed no statistically significant differences (p > 0.05). The AUC of peripheral blood NLR, PLR, and SII for predicting cervical lesions were 0.569, 0.582, and 0.572, respectively. The optimal cutoff values were 2.3,176.48, and 603.56. The sensitivity and specificity were 38.6% and 73.6%, 28.8% and 85.7%, 37.5% and 76.4%, respectively. At the same time, the joint testing of the three had the highest efficiency, with sensitivity of 69% and specificity of 45%. Although the peripheral blood NLR, PLR, and SII of the cervical lesions patients were higher than those without cervical lesions in cervical cancer screening abnormal patients, the predictive ROC curve discrimination was low. Therefore, it is not recommended to use preoperative peripheral blood inflammatory markers as markers for cervical cancer screening abnormal patient diversion.
Identifiants
pubmed: 38943072
doi: 10.1186/s12885-024-12561-7
pii: 10.1186/s12885-024-12561-7
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
780Informations de copyright
© 2024. The Author(s).
Références
Yang Q, Zhou Q, He X, et al. Retrospective analysis of the incidence and predictive factors of parametrial involvement in FIGO IB1 cervical cancer[J]. J Gynecol Obstet Hum Reprod. 2021;50(8):102145.
pubmed: 33848645
doi: 10.1016/j.jogoh.2021.102145
Hall MT, Smith MA, Simms KT, et al. Elimination of cervical cancer in Tanzania: Modelled analysis of elimination in the context of endemic HIV infection and active HIV control[J]. Int J Cancer. 2021;149(2):297–306.
pubmed: 33634857
doi: 10.1002/ijc.33533
Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis[J]. Lancet Glob Health. 2020;8(2):e191–203.
pubmed: 31812369
doi: 10.1016/S2214-109X(19)30482-6
Blake J. The elimination of Cervical Cancer in our Lifetime[J]. J Obstet Gynaecol Can. 2018;40(12):1555–7.
pubmed: 30527069
doi: 10.1016/j.jogc.2018.08.019
Taghavi K, Moono M, Asangbeh S, et al. Strengthening global commitment to eliminating cervical cancer: what lessons from the past can we apply to the future?[J]. J Glob Health. 2020;10(2):20385.
doi: 10.7189/jogh.10.020385
Perkins RB, Guido RS, Castle PE, et al. 2019 ASCCP Risk-Based Management Consensus guidelines for abnormal cervical Cancer screening tests and Cancer Precursors[J]. J Low Genit Tract Dis. 2020;24(2):102–31.
pubmed: 32243307
pmcid: 7147428
doi: 10.1097/LGT.0000000000000525
Kang Y, Zhu X, Lin Z et al. Compare the Diagnostic and Prognostic Value of MLR, NLR and PLR in CRC Patients[J]. Clin Lab, 2021,67(9).
Huang Z, Fu Z, Huang W, et al. Prognostic value of neutrophil-to-lymphocyte ratio in sepsis: a meta-analysis[J]. Am J Emerg Med. 2020;38(3):641–7.
pubmed: 31785981
doi: 10.1016/j.ajem.2019.10.023
Huang H, Liu Q, Zhu L, et al. Prognostic value of preoperative systemic Immune-inflammation index in patients with cervical Cancer[J]. Sci Rep. 2019;9(1):3284.
pubmed: 30824727
pmcid: 6397230
doi: 10.1038/s41598-019-39150-0
Zhang K, Hua YQ, Wang D, et al. Systemic immune-inflammation index predicts prognosis of patients with advanced pancreatic cancer[J]. J Transl Med. 2019;17(1):30.
pubmed: 30658662
pmcid: 6339361
doi: 10.1186/s12967-019-1782-x
Cupp MA, Cariolou M, Tzoulaki I, et al. Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies[J]. BMC Med. 2020;18(1):360.
pubmed: 33213430
pmcid: 7678319
doi: 10.1186/s12916-020-01817-1
Inoue H, Kosuga T, Kubota T, et al. Significance of a preoperative systemic immune-inflammation index as a predictor of postoperative survival outcomes in gastric cancer[J]. World J Surg Oncol. 2021;19(1):173.
pubmed: 34118953
pmcid: 8199826
doi: 10.1186/s12957-021-02286-3
Zhao M, Duan X, Mi L, et al. Prognosis of hepatocellular carcinoma and its association with immune cells using systemic inflammatory response index[J]. Future Oncol. 2022;18(18):2269–88.
pubmed: 35440159
doi: 10.2217/fon-2021-1087
Toyoda J, Sahara K, Maithel SK, et al. Prognostic utility of systemic Immune-inflammation index after resection of Extrahepatic Cholangiocarcinoma: results from the U.S. Extrahepatic biliary malignancy Consortium[J]. Ann Surg Oncol. 2022;29(12):7605–14.
pubmed: 35768667
doi: 10.1245/s10434-022-12058-2
Ji Y, Wang H. Prognostic prediction of systemic immune-inflammation index for patients with gynecological and breast cancers: a meta-analysis[J]. World J Surg Oncol. 2020;18(1):197.
pubmed: 32767977
pmcid: 7414550
doi: 10.1186/s12957-020-01974-w
Wu Y, Tu C, Shao C. Inflammatory indexes in preoperative blood routine to predict early recurrence of hepatocellular carcinoma after curative hepatectomy[J]. BMC Surg. 2021;21(1):178.
pubmed: 33794850
pmcid: 8017621
doi: 10.1186/s12893-021-01180-9
Huang Y, Gao Y, Wu Y, et al. Prognostic value of systemic immune-inflammation index in patients with urologic cancers: a meta-analysis[J]. Cancer Cell Int. 2020;20:499.
pubmed: 33061851
pmcid: 7552553
doi: 10.1186/s12935-020-01590-4
Olingy CE, Dinh HQ, Hedrick CC. Monocyte heterogeneity and functions in cancer[J]. J Leukoc Biol. 2019;106(2):309–22.
pubmed: 30776148
doi: 10.1002/JLB.4RI0818-311R
Gao J, Ren Y, Guo H, et al. A new method for predicting survival in stage I non-small cell lung cancer patients: nomogram based on macrophage immunoscore, TNM stage and lymphocyte-to-monocyte ratio[J]. Ann Transl Med. 2020;8(7):470.
pubmed: 32395514
pmcid: 7210133
doi: 10.21037/atm.2020.03.113
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin. 2018;68(6):394–424.
pubmed: 30207593
doi: 10.3322/caac.21492
Xu M, Wu Q, Cai L, et al. Systemic inflammatory score predicts overall survival in patients with cervical Cancer[J]. J Cancer. 2021;12(12):3671–7.
pubmed: 33995642
pmcid: 8120179
doi: 10.7150/jca.56170
Franco AT, Corken A, Ware J. Platelets at the interface of thrombosis, inflammation, and cancer[J]. Blood. 2015;126(5):582–8.
pubmed: 26109205
pmcid: 4520875
doi: 10.1182/blood-2014-08-531582
Şahin F, Aslan AF. Relationship between inflammatory and biological markers and Lung Cancer[J]. J Clin Med, 2018,7(7).
Yin Y, Zhang Y, Li L, et al. Prognostic value of pretreatment lymphocyte-to-monocyte ratio and development of a nomogram in breast Cancer Patients[J]. Front Oncol. 2021;11:650980.
pubmed: 34976782
pmcid: 8719671
doi: 10.3389/fonc.2021.650980
Yıldız HA, Değer MD, Aslan G. Prognostic value of preoperative inflammation markers in non-muscle invasive bladder cancer[J]. Int J Clin Pract. 2021;75(6):e14118.
pubmed: 33636055
doi: 10.1111/ijcp.14118
Danforth DN. The role of chronic inflammation in the development of breast Cancer[J]. Cancers (Basel), 2021,13(15).
Chen L, Kong X, Yan C, et al. The Research Progress on the Prognostic Value of the common hematological parameters in peripheral venous blood in breast Cancer[J]. Onco Targets Ther. 2020;13:1397–412.
pubmed: 32104003
pmcid: 7028387
doi: 10.2147/OTT.S227171
Zhang Y, Sun Y, Zhang Q. Prognostic value of the systemic immune-inflammation index in patients with breast cancer: a meta-analysis[J]. Cancer Cell Int. 2020;20:224.
pubmed: 32528232
pmcid: 7282128
doi: 10.1186/s12935-020-01308-6
Zhu M, Chen L, Kong X, et al. The systemic Immune-inflammation index is an independent predictor of survival in breast Cancer Patients[J]. Cancer Manag Res. 2022;14:775–820.
pubmed: 35241935
pmcid: 8887616
doi: 10.2147/CMAR.S346406
Hu C, Bai Y, Li J, et al. Prognostic value of systemic inflammatory factors NLR, LMR, PLR and LDH in penile cancer[J]. BMC Urol. 2020;20(1):57.
pubmed: 32460817
pmcid: 7251912
doi: 10.1186/s12894-020-00628-z
Zhu X, Song H, Chen Y et al. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in blood to Distinguish Lung Cancer patients from healthy Subjects[J]. Dis Markers, 2020,2020:8844698.
Nøst TH, Alcala K, Urbarova I, et al. Systemic inflammation markers and cancer incidence in the UK Biobank[J]. Eur J Epidemiol. 2021;36(8):841–8.
pubmed: 34036468
pmcid: 8416852
doi: 10.1007/s10654-021-00752-6
Tian T, Lu J, Zhao W, et al. Associations of systemic inflammation markers with identification of pulmonary nodule and incident lung cancer in Chinese population[J]. Cancer Med. 2022;11(12):2482–91.
pubmed: 35384389
pmcid: 9189452
doi: 10.1002/cam4.4606
Tas M, Yavuz A, Ak M, et al. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in discriminating precancerous pathologies from cervical Cancer[J]. J Oncol. 2019;2019:2476082.
pubmed: 31558903
pmcid: 6735215
doi: 10.1155/2019/2476082
Noh JJ, Lim MC, Kim MH et al. The Prognostic Model of Pre-treatment Complete Blood Count (CBC) for recurrence in early cervical Cancer[J]. J Clin Med, 2020,9(9).
Bogani G, Sopracordevole F, Ciavattini A, et al. HPV persistence after cervical surgical excision of high-grade cervical lesions[J]. Cancer Cytopathol. 2024;132(5):268–9.
pubmed: 37747763
doi: 10.1002/cncy.22760
Buskwofie A, David-West G, Clare CA. A review of Cervical Cancer: incidence and Disparities[J]. J Natl Med Assoc. 2020;112(2):229–32.
pubmed: 32278478
Sadri NJ, Moghoofei M, Salmaninejad A, et al. Pathogenic role of exosomes and microRNAs in HPV-mediated inflammation and cervical cancer: a review[J]. Int J Cancer. 2020;146(2):305–20.
doi: 10.1002/ijc.32688
Ilhan ZE, Łaniewski P, Thomas N, et al. Deciphering the complex interplay between microbiota, HPV, inflammation and cancer through cervicovaginal metabolic profiling[J]. EBioMedicine. 2019;44:675–90.
pubmed: 31027917
pmcid: 6604110
doi: 10.1016/j.ebiom.2019.04.028
Vitkauskaite A, Urboniene D, Celiesiute J, et al. Circulating inflammatory markers in cervical cancer patients and healthy controls[J]. J Immunotoxicol. 2020;17(1):105–9.
pubmed: 32364810
doi: 10.1080/1547691X.2020.1755397
Taguchi A, Nakajima Y, Furusawa A, et al. High neutrophil-to-lymphocyte ratio is a predictor of short-term survival for patients with recurrent cervical cancer after radiation-based therapy[J]. J Obstet Gynaecol Res. 2021;47(5):1862–70.
pubmed: 33611808
doi: 10.1111/jog.14712
Trinh H, Dzul SP, Hyder J, et al. Prognostic value of changes in neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and lymphocyte-to-monocyte ratio (LMR) for patients with cervical cancer undergoing definitive chemoradiotherapy (dCRT)[J]. Clin Chim Acta. 2020;510:711–6.
pubmed: 32919942
doi: 10.1016/j.cca.2020.09.008
Wang B, Huang Y, Lin T. Prognostic impact of elevated pre-treatment systemic immune-inflammation index (SII) in hepatocellular carcinoma: a meta-analysis[J]. Med (Baltim). 2020;99(1):e18571.
doi: 10.1097/MD.0000000000018571
Gao Y, Guo W, Cai S, et al. Systemic immune-inflammation index (SII) is useful to predict survival outcomes in patients with surgically resected esophageal squamous cell carcinoma[J]. J Cancer. 2019;10(14):3188–96.
pubmed: 31289589
pmcid: 6603384
doi: 10.7150/jca.30281
Holub K, Biete A. Impact of systemic inflammation biomarkers on the survival outcomes of cervical cancer patients[J]. Clin Transl Oncol. 2019;21(7):836–44.
pubmed: 30470994
doi: 10.1007/s12094-018-1991-4
Zhu M, Feng M, He F, et al. Pretreatment neutrophil-lymphocyte and platelet-lymphocyte ratio predict clinical outcome and prognosis for cervical Cancer[J]. Clin Chim Acta. 2018;483:296–302.
pubmed: 29758203
doi: 10.1016/j.cca.2018.05.025
Origoni M, Cantatore F, Candotti G et al. Prognostic Significance of Neutrophil/Lymphocytes Ratio (NLR) in Predicting recurrence of cervical Dysplasia[J]. Biomed Res Int, 2022,2022:1149789.
Hajizadeh N, Baghestani AR, Pourhoseingholi MA, et al. Evaluation of the factors affecting the cure rate of cervical intra-epithelial neoplasia recurrence using defective Models[J]. J Res Health Sci. 2021;21(3):e524.
doi: 10.34172/jrhs.2021.56
Xu L, Song J. Elevated neutrophil-lymphocyte ratio can be a biomarker for predicting the development of cervical intraepithelial neoplasia[J]. Med (Baltim). 2021;100(28):e26335.
doi: 10.1097/MD.0000000000026335
Taguchi A, Furusawa A, Ito K, et al. Postradiotherapy persistent lymphopenia as a poor prognostic factor in patients with cervical cancer receiving radiotherapy: a single-center, retrospective study[J]. Int J Clin Oncol. 2020;25(5):955–62.
pubmed: 31960184
doi: 10.1007/s10147-020-01623-y
Lee HJ, Kim JM, Chin YJ, et al. Prognostic value of hematological parameters in locally advanced cervical Cancer patients treated with concurrent Chemoradiotherapy[J]. Anticancer Res. 2020;40(1):451–8.
pubmed: 31892600
doi: 10.21873/anticanres.13973